XBP1 Promotes NRAS Pre-B Acute Lymphoblastic Leukaemia Through IL-7 Receptor Signalling and Provides a Therapeutic Vulnerability for Oncogenic RAS
Overview
Authors
Affiliations
Activating point mutations of the RAS gene act as driver mutations for a subset of precursor-B cell acute lymphoblastic leukaemias (pre-B ALL) and represent an ambitious target for therapeutic approaches. The X box-binding protein 1 (XBP1), a key regulator of the unfolded protein response (UPR), is critical for pre-B ALL cell survival, and high expression of XBP1 confers poor prognosis in ALL patients. However, the mechanism of XBP1 activation has not yet been elucidated in RAS mutated pre-B ALL. Here, we demonstrate that XBP1 acts as a downstream linchpin of the IL-7 receptor signalling pathway and that pharmacological inhibition or genetic ablation of XBP1 selectively abrogates IL-7 receptor signalling via inhibition of its downstream effectors, JAK1 and STAT5. We show that XBP1 supports malignant cell growth of pre-B NRAS ALL cells and that genetic loss of XBP1 consequently leads to cell cycle arrest and apoptosis. Our findings reveal that active XBP1 prevents the cytotoxic effects of a dual PI3K/mTOR pathway inhibitor (BEZ235) in pre-B NRAS ALL cells. This implies targeting XBP1 in combination with BEZ235 as a promising new targeted strategy against the oncogenic RAS in NRAS -mutated pre-B ALL.
Mandell J, Diviti S, Xu M, Townsend J Int J Mol Sci. 2024; 25(12).
PMID: 38928295 PMC: 11203805. DOI: 10.3390/ijms25126589.
Salimi A, Schemionek-Reinders M, Huber M, Vieri M, Patterson J, Alten J J Cell Mol Med. 2023; 27(21):3363-3377.
PMID: 37753803 PMC: 10623536. DOI: 10.1111/jcmm.17904.